Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Taysha buys clinic-ready gene therapy from Abeona, bringing Steven Gray's portfolio back in one place

5 years ago

Teamed up with Lyell, Juno/WuXi joint venture files IPO betting on China's CAR-T future

5 years ago

BioMarin CSO disses rivals for the hemophilia A gene therapy crown: Way behind, facing big recruitment challenges and at best a .6 on the gen-one scale

5 years ago

Novartis’ CAR-T partner in China wraps $383M take-private deal engineered by CEO

5 years ago

CF Foundation, Longwood team on new incubator for companies with cutting-edge CF treatments

5 years ago

FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T alternative

5 years ago

Codiak gets a competitor, as Mantra Bio leaves stealth and enters growing exosome space

5 years ago

'Exquisite control': Flagship pulls off $85M rally around Omega Therapeutics' clinical push for epigenetic programming tech

5 years ago

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb

5 years ago

Gilead’s Kite snares a landmark FDA OK on a $373,000 CAR-T therapy — which comes with bragging rights to the first true franchise op

5 years ago

'Missing link': Bayer, Morningside help catapult a new kind of delivery tech to cell and gene therapy

5 years ago

GV's David Schenkein comes in to help mentor — and bankroll — a gene therapy 2.0 player, intrigued by their ‘science heavy’ approach to conquering severe disease

5 years ago

Juno/WuXi's cell therapy venture buys out solid tumor player in China, gaining a discovery engine and portending more M&A to come

5 years ago

Chris Garabedian's incubator leads Series A funding for gene therapy manufacturer/developer combo

5 years ago

J&J-partnered MeiraGTx aims at Biogen with new eye gene therapy data

5 years ago

Engineering an on/off switch for CAR-T out of yeast and Jurassic Park

5 years ago

Playing catch-up, Roche outlines plans for a PhIII hemophilia A program — next year

5 years ago

Merck dangles up to $425 million to team with Flagship’s Foghorn Therapeutics on drugging the shape of DNA

5 years ago

John Reed brings NK cells into Sanofi's CD38 rivalry with J&J — and offers thumbs up for Kiadis' new focus

5 years ago

Flagship execs take a lesson from nature to master ‘gene writing,’ launching a star-studded biotech with big ambitions to cure disease

5 years ago

RA Capital doubles down on Siddhartha Mukherjee's vision for a new cell engineering approach, leading Vor's $110M Series B

5 years ago

A booming Dragonfly is taking its TriNKETs to Copenhagen as the latest Bristol Myers pact spurs expansion plans — outside the US

5 years ago

Ionis, leading MS researcher throw antisense at a new type of brain cells

5 years ago

Freeline nabs $120M, eyes IPO as its gene therapy comes into focus

5 years ago

First page Previous page 45 46 474849 50 51 Next page Last page